.png){kind=logo}
Cathie Wood’s ARK Invest made more than $10 million in trades on March 12, 2026, according to the firm’s daily disclosures. The firm added new positions while trimming several existing holdings. The largest purchases targeted biotech and fintech companies, including CRISPR Therapeutics and PayPay Corp.
ARK acquired 112,815 shares of CRISPR Therapeutics through two funds. The purchases came from the ARK Innovation ETF and the ARK Genomic Revolution ETF. The combined value reached about $5.63 million.
CRISPR Therapeutics develops gene-editing treatments. The investment shows ARK’s continued focus on genomic medicine. The firm has often backed companies that pursue advanced biotechnology.
Meanwhile, ARK also targeted digital payments. It purchased 275,000 shares of PayPay Corp through the ARK Fintech Innovation ETF. The position cost roughly $4.4 million. Could PayPay’s market debut signal stronger institutional interest in digital payment platforms?
CRISPR Therapeutics ranked as ARK’s largest purchase of the day. The firm split the acquisition across two major ETFs that focus on innovation and genomic technologies.
The company develops treatments using gene-editing technology. ARK has long invested in companies working on genomic medicine. The new purchase continues that strategy. ARK also added shares of GeneDx. The firm bought 52,075 shares of the genomic diagnostics company. The purchase reached about $4.43 million.
GeneDx provides genetic testing and diagnostic services. The company operates within the growing precision medicine sector. ARK’s investment reflects interest in genomic data and diagnostic innovation. The firm also purchased shares of Tempus AI. ARK bought 18,820 shares through its funds. The investment totaled about $991,000.
Tempus AI develops artificial intelligence tools for healthcare data. The company analyzes medical information to support treatment decisions. ARK’s purchase expands exposure to AI-driven healthcare technologies.
ARK’s second-largest purchase involved PayPay Corp. The firm bought 275,000 shares through the ARK Fintech Innovation ETF. The purchase cost about $4.4 million. PayPay operates a digital payments platform. The company focuses on mobile transactions and financial services. ARK’s investment aligns with its focus on financial technology.
PayPay shares gained 13.50% during the trading session. The increase followed the company’s Nasdaq debut. The listing drew strong interest from investors. The offering marked the largest US listing by a Japanese company in nearly a decade. Major banks supported the IPO. Goldman Sachs, JPMorgan Chase, Mizuho, and Morgan Stanley served as underwriters.
Market analysts say ARK’s early investment reflects confidence in digital finance growth. PayPay has attracted attention due to rapid user growth and expanding financial services. The platform combines digital payments with additional financial features. Those services support broader fintech adoption. Institutional investors continue to monitor the company’s progress.
While ARK added new positions, the firm also trimmed several holdings. The largest sale involved Teradyne, a chip-testing equipment manufacturer. ARK sold 10,919 Teradyne shares through the ARK Innovation ETF. The transaction generated about $3.3 million. Teradyne shares fell 5.09% during the session.
Read More: Ark Invest Sees Crypto Market Hitting $28 Trillion by 2030: Here’s Why
The sale continues a recent pattern. ARK has reduced its Teradyne position across several days. The move reflects portfolio adjustments. The firm also sold shares of Ionis Pharmaceuticals. ARK sold 43,533 shares through its ARKG ETF. The transaction reached about $3.26 million.
Ionis shares dropped 3.28% that day. The sale follows a broader trend of ARK reducing exposure to the RNA-based drug developer. ARK trimmed two smaller holdings as well. The firm sold 18,392 shares of 10x Genomics. The transaction totaled roughly $376,000 across ARKK and ARKG.
Finally, ARK reduced its position in Circle Internet Group. The firm sold 11,194 shares through the ARK Innovation ETF. The sale reached about $1.26 million. Circle operates within blockchain payments and stablecoin infrastructure. The adjustment forms part of ARK’s broader portfolio rebalancing strategy.
ARK Invest made more than $10 million in trades on March 12, adding PayPay, CRISPR Therapeutics, GeneDx, and Tempus AI while cutting Teradyne, Ionis, 10x Genomics, and Circle. The moves show Cathie Wood’s firm still favors fintech and healthcare innovation as it reshapes its portfolio.
